Michiel Tent summarises 6 abstracts from the MS Virtual 2020 and its Encore Event:
- EDSS and age are risk factors for severe COVID-19 in MS patients
Louapre C. MSVIRTUAL2020, Abstract SS02.06. - Brain alterations at onset of first demyelinating event
Collorone S. MSVIRTUAL2020, Abstract LB01.04. - Amantadine, modafinil, and methylphenidate for MS-related fatigue
Nourbakhsh B, et al. MSVIRTUAL2020, Abstract PS13.03. - Masitinib possible new treatment of progressive MS
Vermersch P, et al. MSVIRTUAL2020, Abstract FC04.01. - No new safety signals in ofatumumab open-label data
Cross AH, et al. MSVIRTUAL2020, Abstract P0234. - The MS prodrome
Tremlett H. MSVIRTUAL2020, Abstract PL01.01.
- EDSS and age are risk factors for severe COVID-19 in MS patients
Posted on
Previous Article
« Experts recommend three dosing protocols for medical cannabis when treating chronic pain Next Article
Numerous drugs can spawn a broad range of arrhythmias »
« Experts recommend three dosing protocols for medical cannabis when treating chronic pain Next Article
Numerous drugs can spawn a broad range of arrhythmias »
Table of Contents: MS Virtual 2020
Featured articles
Registry participation can enhance quality of rheumatology care
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
T2T approach in women with RA associated with increased fertility
Positive results for vagus nerve stimulation in RA
Machine learning to aid evaluation of ANA pattern and titer
ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease
Registry participation can enhance quality of rheumatology care
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
November 18, 2024
First-line moderate-efficacy DMTs show similar efficacy
June 16, 2021
Tolebrutinib reduces brain lesions in very active MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com